The Patented Medicine Prices Review Board released the July 2017 issue of its NEWSletter. Highlights include:

  • an update on the status of proposed amendments to the Patented Medicine Regulations(Regulations) in respect of changes to the regulations of patented drug prices;
  • a reminder that patentees are required under the Regulations to properly complete Block 5 information by filing “publicly available ex-factory prices for each dosage form, strength and package size in which their product is sold to each class of customer in each country set out in the schedule”; and
  • notice of recent and forthcoming publications, including: CompassRx, 3rd edition, which reports on prescription drug expenditures by Canada’s public drug plans; the first of three reports on Canadian public drug plan formularies to be released in fall 2017; Generics360, which focuses on generic drug pricing in Canada and internationally; and a report entitled Potential savings from biosimilars in Canada.